Table 4. Multivariable factors associated with sexual function (FSFI* score) among sexually active women in SPRINT.
| Variable | Model 1 – Any antihypertensive(s) versus no antihypertensives | Model 2 – Class of antihypertensive | ||
|---|---|---|---|---|
|
| ||||
| Beta for FSFI score (95% CI) | P-value | Beta for FSFI score (95% CI) | P-value | |
| Antihypertensive class | ||||
| No antihypertensive use (v. any) | 2.73 (-0.22,5.68) | 0.069 | - | - |
| Beta-blocker use (v. no) | - | - | -0.57 (-2.81,1.66) | 0.61 |
| Calcium channel blocker use (v. no) | - | - | 0.39 (-1.65,2.43) | 0.71 |
| Diuretic use (v. no) | - | - | -1.42 (-3.35,0.5) | 0.146 |
| ACEI/ARB† use (v. no) | - | - | -1.08 (-2.97,0.8) | 0.26 |
| Other Antihypertensive med use (v. no) | - | - | 0.37 (-3.19,3.92) | 0.84 |
| Age (per 10 years increase) | 0.75 (-0.71,2.2) | 0.31 | 0.54 (-0.93,2.01) | 0.47 |
| Race/Ethnicity | ||||
| White | Ref | 0.12 | Ref | 0.159 |
| African-American | 2.37 (0.14,4.59) | 2.33 (0.07,4.6) | ||
| Hispanic | 2.53 (-0.27,5.32) | 2.07 (-0.77,4.92) | ||
| Other | -1.02 (-6.05,4.01) | -1.14 (-6.29,4.01) | ||
| Education | ||||
| Did not attend college | Ref | 0.14 | Ref | 0.114 |
| Some college | 2.36 (-0.2,4.92) | 2.57 (-0.04,5.18) | ||
| College graduate | 3.24 (0.31,6.16) | 3.4 (0.44,6.36) | ||
| Graduate or professional school | 2.43 (-0.34,5.2) | 2.58 (-0.21,5.38) | ||
| Lives with others (v. no) | 1.27 (-0.86,3.39) | 0.24 | 0.99 (-1.19,3.17) | 0.37 |
| SBP‡ (per 10 mm Hg increase) | 0.03 (-0.76,0.82) | 0.93 | 0.01 (-0.81,0.82) | 0.99 |
| DBP§ (per 10 mm Hg increase) | 0.78 (-0.34,1.91) | 0.17 | 0.69 (-0.46,1.84) | 0.24 |
| Use of SSRI‖ | -1.04 (-4.27,2.2) | 0.53 | -1.31 (-4.65,2.04) | 0.44 |
| Use of hormone therapy | -3.14 (-6.4,0.12) | 0.059 | -3.42 (-6.74,-0.1) | 0.044 |
| Medical comorbidities | ||||
| CKD¶ | 0.55 (-1.72,2.83) | 0.63 | -0.05 (-2.51,2.41) | 0.97 |
| Hyperlipidemia | 0.96 (-0.85,2.76) | 0.30 | 0.93 (-0.91,2.77) | 0.32 |
| Cardiovascular disease | 0.14 (-2.58,2.86) | 0.92 | 0.28 (-2.55,3.1) | 0.85 |
Each estimate is adjusted for all other variables with estimates shown; in Model 2, results for each class of antihypertensive use are adjusted for use of other classes of antihypertensives.
*
Female Sexual Function Index--higher scores indicate better sexual function,
†
Angiotensin converting enzyme inhibitor/angiotensin receptor blocker,
‡
systolic blood pressure,
§
diastolic blood pressure,
‖
selective serotonin reuptake inhibitor,
¶
chronic kidney disease